Stock Analysis

Retrophin, Inc. (NASDAQ:RTRX): Will The Growth Last?

NasdaqGM:TVTX
Source: Shutterstock

The most recent earnings update Retrophin, Inc.'s (NASDAQ:RTRX) released in December 2018 signalled that losses became smaller relative to the prior year's level as a result of recent tailwinds Below is a brief commentary on my key takeaways on how market analysts view Retrophin's earnings growth outlook over the next couple of years and whether the future looks brighter. Note that I will be looking at net income excluding extraordinary items to get a better understanding of the underlying drivers of earnings.

View our latest analysis for Retrophin

Market analysts' prospects for this coming year seems relatively unexciting, with earnings continuing to flop around in the negative territory, generating -US$100.8m in 2020. However, earnings should move into an upward trajectory, reaching -US$117.4m in 2021, before plateauing down to -US$12.6m in 2022.

NasdaqGM:RTRX Past and Future Earnings, March 27th 2019
NasdaqGM:RTRX Past and Future Earnings, March 27th 2019

While it’s helpful to be aware of the rate of growth year by year relative to today’s value, it may be more beneficial to gauge the rate at which the company is moving every year, on average. The advantage of this method is that it ignores near term flucuations and accounts for the overarching direction of Retrophin's earnings trajectory over time, be more volatile. To calculate this rate, I've appended a line of best fit through the forecasted earnings by market analysts. The slope of this line is the rate of earnings growth, which in this case is 47%. This means that, we can anticipate Retrophin will grow its earnings by 47% every year for the next couple of years.

Advertisement

Next Steps:

For Retrophin, there are three pertinent aspects you should further examine:

  1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Valuation: What is RTRX worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether RTRX is currently mispriced by the market.
  3. Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of RTRX? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NasdaqGM:TVTX

Travere Therapeutics

A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.

High growth potential and good value.

Advertisement